|

An Ophthalmic Safety Study in Patients With Breast Cancer

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2025-03-04
Est. completion2027-07-06
Eligibility
Age18 Years – 130 Years
Healthy vol.Accepted
Locations12 sites
View on ClinicalTrials.gov →

NCT06767462

Summary

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Eligibility

Age: 18 Years – 130 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Signed informed consent in the qualifying study.
2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
4. Meets all the eligibility criteria in the qualifying study

Exclusion Criteria:

1. Patients not randomized and not receiving study assigned treatment in a qualifying study.
2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Conditions3

Breast CancerCancerOphthalmic Safety in Patients With Breast Cancer

Locations12 sites

Research Site
La Jolla, California, 92093
Research Site
Palo Alto, California, 94304
Research Site
San Diego, California, 92123
Research Site
Iowa City, Iowa, 52242
Research Site
New York, New York, 10029

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.